|
Diabetes, Vol 49, Issue 5 759-767, Copyright © 2000 by American Diabetes Association
A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice
Y Fukui, S Masui, S Osada, K Umesono and K Motojima
Department of Biochemistry, School of Pharmaceutical Sciences, Toho University, Chiba, Japan.
Thiazolidinediones (TZDs) reduce insulin resistance in type 2 diabetes by
increasing peripheral uptake of glucose, and they bind to and activate the
transcriptional factor peroxisome proliferator-activated receptor-gamma
(PPAR-gamma). Studies have suggested that TZD-induced activation of
PPAR-gamma correlates with antidiabetic action, but the mechanism by which
the activated PPAR-gamma is involved in reducing insulin resistance is not
known. To examine whether activation of PPAR-gamma directly correlates with
antidiabetic activities, we compared the effects of 4 TZDs (troglitazone,
pioglitazone, BRL-49653, and a new derivative, NC-2100) on the activation
of PPAR-gamma in a reporter assay, transcription of the target genes,
adipogenesis, plasma glucose and triglyceride levels, and body weight using
obese KKAy mice. There were 10- to 30-fold higher concentrations of NC-2100
required for maximal activation of PPAR-gamma in a reporter assay system,
and only high concentrations of NC-2100 weakly induced transcription of the
PPAR-gamma but not PPAR-alpha target genes in a whole mouse and
adipogenesis of cultured 3T3L1 cells, which indicates that NC-2100 is a
weak PPAR-gamma activator. However, low concentrations of NC-2100
efficiently lowered plasma glucose levels in KKAy obese mice. These results
strongly suggest that TZD-induced activation of PPAR-gamma does not
directly correlate with antidiabetic (glucose-lowering) action.
Furthermore, NC-2100 caused the smallest body weight increase of the 4
TZDs, which may be partly explained by the finding that NC-2100 efficiently
induces uncoupling protein (UCP)-2 mRNA and significantly induces UCP1 mRNA
in white adipose tissue (WAT). NC-2100 induced UCP1 efficiently in
mesenteric WAT and less efficiently in subcutaneous WAT, although
pioglitazone and troglitazone also slightly induced UCP1 only in mesenteric
WAT. These characteristics of NC-2100 should be beneficial for humans with
limited amounts of brown adipose tissue.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. C. Carmona, K. Louche, B. Lefebvre, A. Pilon, N. Hennuyer, V. Audinot-Bouchez, C. Fievet, G. Torpier, P. Formstecher, P. Renard, et al.
S 26948: a New Specific Peroxisome Proliferator Activated Receptor {gamma} Modulator With Potent Antidiabetes and Antiatherogenic Effects
Diabetes,
November 1, 2007;
56(11):
2797 - 2808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Si, S. Palani, A. Jayaraman, and K. Lee
Effects of forced uncoupling protein 1 expression in 3T3-L1 cells on mitochondrial function and lipid metabolism
J. Lipid Res.,
April 1, 2007;
48(4):
826 - 836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Burgermeister, A. Schnoebelen, A. Flament, J. Benz, M. Stihle, B. Gsell, A. Rufer, A. Ruf, B. Kuhn, H. P. Marki, et al.
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-{gamma} (PPAR{gamma}) Recruits PPAR{gamma}-Coactivator-1{alpha}, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro
Mol. Endocrinol.,
April 1, 2006;
20(4):
809 - 830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Bogacka, B. Ukropcova, M. McNeil, J. M. Gimble, and S. R. Smith
Structural and Functional Consequences of Mitochondrial Biogenesis in Human Adipocytes in Vitro
J. Clin. Endocrinol. Metab.,
December 1, 2005;
90(12):
6650 - 6656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith
Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo
Diabetes,
May 1, 2005;
54(5):
1392 - 1399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sell, J. P. Berger, P. Samson, G. Castriota, J. Lalonde, Y. Deshaies, and D. Richard
Peroxisome Proliferator-Activated Receptor {gamma} Agonism Increases the Capacity for Sympathetically Mediated Thermogenesis in Lean and ob/ob Mice
Endocrinology,
August 1, 2004;
145(8):
3925 - 3934.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Tiraby, G. Tavernier, C. Lefort, D. Larrouy, F. Bouillaud, D. Ricquier, and D. Langin
Acquirement of Brown Fat Cell Features by Human White Adipocytes
J. Biol. Chem.,
August 29, 2003;
278(35):
33370 - 33376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies
PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion
Diabetes,
February 1, 2003;
52(2):
291 - 299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Sato, C. Kuriki, Y. Fukui, and K. Motojima
Dual Promoter Structure of Mouse and Human Fatty Acid Translocase/CD36 Genes and Unique Transcriptional Activation by Peroxisome Proliferator-activated Receptor alpha and gamma Ligands
J. Biol. Chem.,
May 3, 2002;
277(18):
15703 - 15711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. S. Camp, A. Chaudhry, and T. Leff
A Novel Potent Antagonist of Peroxisome Proliferator-Activated Receptor {{gamma}} Blocks Adipocyte Differentiation But Does Not Revert the Phenotype of Terminally Differentiated Adipocytes
Endocrinology,
July 1, 2001;
142(7):
3207 - 3213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-H. Kim, T. M. Lewin, and R. A. Coleman
Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5. SELECTIVE INHIBITION BY TRIACSIN C AND THIAZOLIDINEDIONES
J. Biol. Chem.,
June 29, 2001;
276(27):
24667 - 24673.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Diabetes Association.
|
|
| |
|